by NanoVation | Mar 29, 2026 | 2026, News
NanoVation’s ligand-free lcLNP™ achieves complete B cell depletion in NHP at 0.1 mg/kg Most lipid nanoparticle (LNP) platforms face the same constraint: they are cleared rapidly by the liver, which makes it hard to deliver nucleic acids to tissues beyond that organ....
by NanoVation | Jul 10, 2025 | 2025, News
News NanoVation wins “Deal of the Year” award from Life Sciences BC We’re thrilled to share that NanoVation Therapeutics has been awarded the prestigious Deal of the Year award at the 27th Annual Life Sciences BC Awards! This recognition celebrates our partnership...
by NanoVation | Mar 18, 2025 | 2025, News
News NanoVation featured on Biotech TV NanoVation TherapeuticsTM was recently featured by the online media outlet Biotech TV, which interviewed company co-founders Drs Pieter Cullis and Jay Kulkarni. The host, BiotechTV founder Brad Loncar, opens the discussion by...
by NanoVation | Nov 19, 2024 | 2024, News
News NTx announces expansion of Board of Directors & completion of funding round led by Convergent Ventures Vancouver, British Columbia – November 19, 2024 –NanoVation Therapeutics, a platform company developing innovative technologies to overcome barriers to...
by NanoVation | Sep 18, 2024 | 2024, News
News NanoVation Therapeutics announces multi-target partnership with Novo Nordisk to develop genetic medicines targeting cardiometabolic and rare diseases NanoVation will receive research funding and is eligible to receive up to approximately US$600 million in...
by NanoVation | Aug 13, 2024 | 2024, 2024, News, Publications
Publication NTx chemistry team publishes in J. of Organic Chemistry Claisen Self-Condensation of Lactones in the Synthesis of Ionizable Lipids Nabi et al. 13 August 2024 Co-authored by NanoVation’s Ardalan Nabi, N. D. Prasad Atmuri, Deaglan Arnold, Fariba Saadati, Huy...
